| Private Placement / Financing Transactions
Supira Medical: The company raised $120 million of Series E venture funding in a deal led by Novo Holdings and Qatar Investment Authority on March 26, 2025, putting the company’s pre-money valuation at $300 million. PA MedTech VC Fund, Cormorant Asset Management, 415 Capital, AMED Ventures, Unorthodox Ventures and The Capital Partnership also participated in the round. The company is a developer of a percutaneous ventricular assist device designed to treat high-risk coronary intervention and cardiogenic shock.
Character Biosciences: The company raised $93 million of Series B venture funding in a deal led by aMoon Fund and Luma Group on March 25, 2025, putting the company’s pre-money valuation at $87 million. Bausch + Lomb, Jefferson Life Sciences, Catalio Capital Management, Innovation Endeavors, S32, KdT Ventures, and other undisclosed investors also participated in the round. The company is a developer of a precision medicine business developing targeted therapies for progressive polygenic diseases, such as ophthalmology.
Tempero Bio: The company raised $70 million of Series B venture funding in a deal led by 8VC on March 24, 2025, putting the company’s pre-money valuation at $70 million. Aditum Bio, Khosla Ventures, and other undisclosed investors also participated in the round. The company is a developer of transformative therapies designed for treating and preventing substance use disorders.
Hillstar Bio: The company raised $66.5 million of Series A venture funding in a deal led by Novo Holdings, Hummingbird Bioscience and LifeArc Ventures on March 25, 2025, putting the company’s pre-money valuation at $38.5 million. The company is a developer of autoimmune drugs intended to selectively target and deplete pathogenic immune cells while sparing healthy ones.
Cala Health: The company raised an esimated $50 million of Series C venture funding in a deal led by Vertex Growth and Nexus Neurotech on March 25, 2025, putting the company’s pre-money valuation at $100 million. GV, Action Potential Venture Capital, Johnson & Johnson Innovation – JJDC, Ascension Ventures, OSF Ventures, Pegasus Tech Ventures, Kirin Health Innovation Fund, Fiscus Ventures, Alumni Ventures, PEAK6 Strategic Capital, Lux Capital, Lightstone Ventures, Triventures and Reimagined Ventures also participated in the round. The company is a developer of neuromodulation devices designed to optimize the standard of care for chronic diseases, with a frst device providing non-invasive therapy for hand tremor.
Owlstone Medical: The company raised an estimated $29.3 million of Series E venture funding in a deal led by Ventura Capital on March 25, 2025. Aviva Ventures, Horizons Ventures, Gates Foundation, Cystic Fibrosis Foundation, and other undisclosed investors also participated in the round. The company is a developer of a healthcare breathalyzer product designed to focus on non-invasive diagnostics for the early detection of disease and for use in precision medicine.
GreenLight Biosciences: The company received $25 million of development capital from Just Climate on March 26, 2025. The company is a developer of a cell-free bioprocessing platform designed to create RNA-based products.
NEXT Life Sciences: The received investment towards a $20 million Series A venture funding on March 24, 2025. The company is a developer of a non-hormonal male contraceptive solution.
Evident Vascular: The company raised an estimated $19 million of Series B venture funding in a deal led by ShangBay Capital on March 25, 2025, putting the company’s pre-money valuation at $75 million. Vensana Capital also participated in the round. The company is a developer of intravascular ultrasound (IVUS) technology intended to deliver improved image interpretation.
Alume Biosciences: The company closed on $15 million of an undisclosed targeted amount of Series C venture funding on March 26, 2025. The company is a developer of a nerve illumination technology designed to help doctors perform precision surgery.
Notable Systems: The company raised $11.9 million of Series B venture funding from undisclosed investors on March 25, 2025, putting the company’s pre-money valuation at $31.1 million. The company is a developer of an AI-powered platform designed to extract and process sensitive healthcare data.
Hubble Therapeutics: The company raised $7.3 million of Series A venture funding in a deal led by Wisconsin Alumni Research Foundation on March 25, 2025. The company is a developer of a gene therapy platform designed for a rare genetic eye disorder that typically presents with severe progressive visual impairment.
Arpeggio: The company raised $4 million of venture funding from undisclosed investors on March 26, 2025. The company is a developer of a drug assessment technology designed to find new therapeutic targets for hard to treat diseases like cancer.
Xealth: The company raised an undisclosed amount of venture funding from Morningside Group on March 25, 2025. The company is an operator of digital health programs intended to scale healthcare system workflows.
|
